
Erdanib is identified on this website as an erdafitinib-containing product in stated 4 mg and 5 mg strengths.
Product identity
| Characteristic | Information |
|---|---|
| Product | Erdanib |
| Active ingredient | Erdafitinib |
| Stated strengths | 4 mg and 5 mg |
| Drug class | FGFR tyrosine kinase inhibitor |
| Therapeutic category | Antineoplastic |
| Reference product | BALVERSA |
| Original discovery/development | Astex Pharmaceuticals and Janssen |
| Erdanib manufacturer | Drug International Limited |
Therapeutic role
Erdafitinib is used in selected patients with advanced urothelial carcinoma carrying susceptible FGFR3 alterations. Current U.S. labeling requires molecular selection using an FDA-approved companion diagnostic.
Reference product
BALVERSA is the established branded erdafitinib product in the U.S. and EU regulatory sources reviewed.
Development history
Erdafitinib was discovered through Astex’s FGFR research program in collaboration with Janssen. Astex reports that the collaboration began in 2008 and that Janssen was responsible for clinical development and commercialization.
Safety
Important safety considerations include ocular toxicity, hyperphosphatemia, stomatitis, nail disorders, palmar-plantar erythrodysesthesia and other adverse effects.
Product verification
The actual Erdanib package should be checked against reliable manufacturer and regulatory documentation before use.